THE 14th Sugiyama Laboratory Open Symposium
“From Drug screening, selection, translation to clinical development”

Date : Oct. 11 (Fri) 12:30-17:50 , 2019
Place : RIKEN Yokohama Main Building Hall
Language:English
Registration Fee : Free
Banquet fee: \ 3,000 18:00-19:45
Registration ; mail to yslab.secretary [at] ml.riken.jp with below information.
name/affiliation/mail address/banquet(attend or not)
※ no later than Sep. 20th, 2019 Japan time
※ We will inform all participants about the password for viewing abstract.
※ The final version of the abstract has been published. (October 9th)
This Symposium is a part of the RIKEN Symposium Series.
Abstract The download period has ended.
Program
12:30-12:35 Opening remarks
Yuichi Sugiyama (Sugiyama Laboratory, RIKEN)
12:35-13:15 【Key note Lecture】
ADME Characterization and Application of Translational Modeling in Drug Discovery;
impact, opportunities and challenges
Marjoleen Nijsen (AbbVie Inc.)
13:15-13:45 【Special Lecture】
Translational and reverse translational research on pediatric liver diseases
Hisamitsu Hayashi (The University of Tokyo)
13:45-17:05 [Round table discussion on “From Drug screening, selection, translation to
clinical development”]
13:45-14:10 Prediction of major clearance pathway using in silico approach.
Kimio Tohyama (Takeda Pharmaceutical Company
Limited)
14:10-14:35 Application of in silico ADME prediction in drug discovery stage.
Daisuke Sugiyama (DAIICHI SANKYO COMPANY,
LIMITED)
14:35-15:00 Prediction of human hepatic clearance for OATP1B substrate drugs by in vitro-in
vivo extrapolation approaches
Yoshitane Nozaki (Eisai Co., Ltd.)
15:00-15:25 Coffee break
15:25-15:50 Extended Clearance Classification System (ECCS) approach in drug discovery -
OAT2 contribution to hepatic clearance for
ECCS1A compounds
Emi Kimoto (Pfizer Inc.)
15:50-16:15 Pharmacokinetics and Pharmacogenomics Characterization of Compound X -
From Discovery to Clinic.
Ryota Kikuchi (AbbVie Inc.)
16:15-16:40 Prediction and mechanistic evaluation of clinical DDI with transporter endogenous
biomarkers.
Kenta Yoshida (Genentech inc.)
16:40-17:05 The Strategic implementation of MIDD in the early clinical development.
Akihiro Yamada (Astellas Pharma Inc.)
17:05-17:50 General discussion
Yuichi Sugiyama (Sugiyama Laboratory,
RIKEN)
18:00-19:45 Banquet (Cafeteria at Yokohama RIKEN)
Contact to:Sugiyama's Laboratory
Email: yslab.secretary [at] ml.riken.jp
HP: http://www.sugiyamalab.com/
Tel: 045‐503‐9210